Mustang Bio Inc
MBIO
Company Profile
Business description
Mustang Bio Inc is a clinical-stage biopharmaceutical company focused on translating today's medical breakthroughs into potential cures for difficult-to-treat cancers. It acquires rights to these technologies by licensing or otherwise acquiring an ownership interest in the technologies, funding their research and development, and eventually either out-licensing or bringing the technologies to market. Its pipeline is currently focused on the core areas of gene therapies for rare genetic disorders, chimeric antigen receptor (CAR) engineered T cell (CAR T) therapies for hematologic malignancies, and CAR T therapies for solid tumors.
Contact
95 Sawyer Road
Suite 110
WalthamMA02453
USAT: +1 781 652-4500
Sector
Healthcare
Stock type
Defensive
Industry
Biotechnology
Fiscal Year End
31 December 2026
Employees
4
Stocks News & Analysis
stocks
ASX payments utility looks overvalued
Australia’s invisible payments utility earns narrow moat yet valuation looks lofty.
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 8,823.20 | 71.40 | -0.80% |
| CAC 40 | 7,716.86 | 52.35 | -0.67% |
| DAX 40 | 24,952.48 | 151.88 | -0.60% |
| Dow JONES (US) | 51,179.87 | 341.41 | -0.66% |
| FTSE 100 | 10,410.21 | 48.29 | -0.46% |
| HKSE | 23,785.79 | 344.71 | -1.43% |
| NASDAQ | 27,538.69 | 61.20 | -0.22% |
| Nikkei 225 | 69,042.11 | 993.60 | -1.42% |
| NZX 50 Index | 13,691.85 | 7.81 | 0.06% |
| S&P 500 | 7,801.77 | 17.16 | -0.22% |
| S&P/ASX 200 | 8,660.90 | 66.80 | -0.77% |
| SSE Composite Index | 3,811.90 | 30.29 | -0.79% |